CLINICAL EVALUATION OF ADRIAMYCIN, A NEW ANTITUMOUR ANTIBIOTIC
CLINICAL EVALUATION OF ADRIAMYCIN, A NEW ANTITUMOUR ANTIBIOTIC
复制标题
DOI：
10.1136/bmj.3.5669.503
复制
发表时间：
1969-01-01
影响因子：
105.7
通讯作者：
FOSSATIB.F
中科院分区：
文献类型：
--
作者：
BONADONNA, G;MONFARDINI, S;FOSSATIB.F
阿霉素是蒽环类的一种新的抗肿瘤抗生素，其结构式与柔红霉素非常相似，已被证明具有有效的肿瘤生长抑制特性，对儿童恶性肿瘤特别有效。虽然阿霉素产生的副作用比柔红霉素高，即口腔炎和脱发，但治疗时可以使用较低的剂量。
Adriamycin, a new antitumour antibiotic of the anthracycline group with a structural formula very similar to daunorubicin, has proved to have potent tumour-growth-inhibiting properties, and to be particularly effective in childhood malignancies. Though adriamycin produces a higher percentage of side-effects than daunorubicin—namely, stomatitis and alopecia—a lower dosage may be used for therapy.